Immunovia AB (publ) (LON:0G8X)

Market Cap	8.17M
Revenue (ttm)	46.49K
Net Income (ttm)	-9.46M
Shares Out	n/a
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,369
Average Volume	33,167
Open	0.434
Previous Close	0.432
Day's Range	0.418 - 0.435
52-Week Range	0.418 - 7.830
Beta	1.44
RSI	24.83
Earnings Date	Feb 25, 2025

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 11
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0G8X

Financial Performance

In 2023, Immunovia AB's revenue was 1.58 million, an increase of 37.55% compared to the previous year's 1.15 million. Losses were -309.44 million, 84.1% more than in 2022.

Financial numbers in SEK